---
run_id: halo-evidence-vs-diagnosis-validation-v11-vanilla-06
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
model_condition: vanilla
run_number: 6
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 1024
seed: 601
prompt_source: condition packet (vanilla) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 18fa1d51f6167dbbf1f7ece676734d5cdb459384bca25e1508dd96cd4745e42d
source_packet: the frozen Advisor prompt alone, with no added material - see run-packet.md
source_packet_sha256: 18fa1d51f6167dbbf1f7ece676734d5cdb459384bca25e1508dd96cd4745e42d
condition_packet_sha256: 18fa1d51f6167dbbf1f7ece676734d5cdb459384bca25e1508dd96cd4745e42d
output_file: model-outputs/vanilla-06.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - vanilla (run 06)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v11-v1`, condition `vanilla`, run 6 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 601, on the frozen condition packet.

## Output

I recommend the **Claim File Review**.

### The Recommendation
You should advise the CEO to commit to the Claim File Review. While the executive team is celebrating a "strong quarter," your data suggests this growth is an illusion created by financial incentives (bundle pricing) and "roadmap selling" rather than actual product-market fit.

The core risk is that you are scaling a "manager's toy"—a tool used for retrospective audits and enablement meetings—rather than an adjuster's utility. The Usage Quality Sprint only tracks *if* they click; the Commercial Cleanroom only tracks *if* they pay. Neither tells you *why* the front-line adjusters are abandoning the tool after two days or why health-liability users can't justify the output.

The Claim File Review is the only option that exposes the "truth" of the workflow: whether SignalPath is actually solving a problem or simply creating a draft that adjusters find too risky or tedious to use. This is the only evidence base strong enough to decide whether to pivot, persevere, or narrow the focus before you lock in next year's budget.

### The Strongest Reason Against It
**It is slow and qualitative.** Unlike the Usage Quality Sprint or the Cleanroom, this does not provide a clean, automated dashboard for the board. It requires manual labor from your team and time from your customers. In a high-pressure environment where the executive team currently feels "aligned" and "disciplined," presenting qualitative evidence that contradicts a 16% rise in bookings may be perceived as "product pessimism" or an attempt to slow down commercial momentum.

### The Observable Evidence That Would Change My Mind
I would switch my recommendation to the **Commercial Cleanroom** if you discovered that the "bundle price" was a negligible driver of renewals (e.g., if 80% of the expansion dollars came from accounts that *did not* receive the discount). If the financial growth is organic and decoupled from the pricing incentive, then the primary risk shifts from "Product Value" to "Pricing Strategy," making the Cleanroom the priority to protect your margins.
